SEARCH

SEARCH BY CITATION

References

  • 1
    Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ et al. (2001) Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 344, 710719.
  • 2
    Hagell P, Piccini P, Bjorklund A, Brundin P, Rehncrona S, Widner H, Crabb L, Pavese N, Oertel WH, Quinn N et al. (2002) Dyskinesias following neural transplantation in Parkinson’s disease. Nat Neurosci 5, 627628.
  • 3
    Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J et al. (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 54, 403414.
  • 4
    Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 15, 285320.
  • 5
    Fink JS, Weaver DR, Rivkees SA, Peterfreund RA, Pollack AE, Adler EM & Reppert SM (1992) Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptor in rat striatum. Mol Brain Res 14, 186195.
  • 6
    Schiffmann SN, Jacobs O & Vanderhaegen JJ (1991) Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 57, 10621067.
  • 7
    Tong J, Fitzmaurice PS, Ang LC, Furukawa Y, Guttman M & Kish SJ (2004) Brain dopamine-stimulated adenylyl cyclase activity in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 55, 125129.
  • 8
    Corvol JC, Muriel MP, Valjent E, Feger J, Hanoun N, Girault JA, Hirsch EC & Herve D (2004) Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci 24, 70077014.
  • 9
    Mishra RK, Gardner EL, Katzman R & Makman MH (1974) Enhancement of dopamine-stimulated adenylate cyclase activity in rat caudate after lesions in substantia nigra: evidence for denervation supersensitivity. Proc Natl Acad Sci USA 71, 38833887.
  • 10
    Pifl C, Nanoff C, Schingnitz G, Schutz W & Hornykiewicz O (1992) Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson’s disease. J Neurochem 58, 19972004.
  • 11
    Pifl C, Reither H & Hornykiewicz O (1992) Functional sensitization of striatal dopamine D1 receptors in the 6-hydroxydopamine-lesioned rat. Brain Res 572, 8793.
  • 12
    Breese GR, Duncan GE, Napier TC, Bondy SC, Iorio LC & Mueller RA (1987) 6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J Pharmacol Exp Ther 240, 167176.
  • 13
    Joyce JN (1991) Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system. Exp Neurol 113, 261276.
  • 14
    Marshall JF, Navarrete R & Joyce JN (1989) Decreased striatal D1 binding density following mesotelencephalic 6-hydroxydopamine injections: an autoradiographic analysis. Brain Res 493, 247257.
  • 15
    Savasta M, Dubois A, Benavides J & Scatton B (1988) Different plasticity changes in D1 and D2 receptors in rat striatal subregions following impairment of dopaminergic transmission. Neurosci Lett 85, 119124.
  • 16
    Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE, Fisone G, Bloch B et al. (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57, 1726.
  • 17
    Hurley MJ, Mash DC & Jenner P (2001) Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson’s disease. Brain Res Mol Brain Res 87, 271279.
  • 18
    Pimoule C, Schoemaker H, Reynolds GP & Langer SZ (1985) [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson’s disease. Eur J Pharmacol 114, 235237.
  • 19
    Shinotoh H, Inoue O, Hirayama K, Aotsuka A, Asahina M, Suhara T, Yamazaki T & Tateno Y (1993) Dopamine D1 receptors in Parkinson’s disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 56, 467472.
  • 20
    Turjanski N, Lees AJ & Brooks DJ (1997) In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson’s disease patients with and without dyskinesias. Neurology 49, 717723.
  • 21
    Herve D, Le Moine C, Corvol JC, Belluscio L, Ledent C, Fienberg AA, Jaber M, Studler JM & Girault JA (2001) Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J Neurosci 21, 43904399.
  • 22
    Zhuang X, Belluscio L & Hen R (2000) G(olf)alpha mediates dopamine D1 receptor signaling. J Neurosci 20, RC91.
  • 23
    Herve D, Levi-Strauss M, Marey-Semper I, Verney C, Tassin JP, Glowinski J & Girault JA (1993) G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase. J Neurosci 13, 22372248.
  • 24
    Hemmings HC Jr, Greengard P, Tung HY & Cohen P (1984) DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310, 503505.
  • 25
    da Cruz e Silva EF, Fox CA, Ouimet CC, Gustafson E, Watson SJ & Greengard P (1995) Differential expression of protein phosphatase 1 isoforms in mammalian brain. J Neurosci 15, 33753389.
  • 26
    Greengard P (2001) The neurobiology of slow synaptic transmission. Science 294, 10241030.
  • 27
    Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA & Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6, 501506.
  • 28
    Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, Herve D, Greengard P & Fisone G (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27, 69957005.
  • 29
    Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G & Cenci MA (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 194, 6675.
  • 30
    Banke TG, Bowie D, Lee H, Huganir RL, Schousboe A & Traynelis SF (2000) Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J Neurosci 20, 89102.
  • 31
    Mangiavacchi S & Wolf ME (2004) D1 dopamine receptor stimulation increases the rate of AMPA receptor insertion onto the surface of cultured nucleus accumbens neurons through a pathway dependent on protein kinase A. J Neurochem 88, 12611271.
  • 32
    Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E & Chase TN (2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54, 15891595.
  • 33
    Svenningsson P, Fienberg AA, Allen PB, Le Moine C, Lindskog M, Fisone G, Greengard P & Fredholm BB (2000) Dopamine D1 receptor-induced gene transcription is modulated by DARPP-32. J Neurochem 75, 248257.
  • 34
    Zachariou V, Sgambato-Faure V, Sasaki T, Svenningsson P, Berton O, Fienberg AA, Nairn AC, Greengard P & Nestler EJ (2006) Phosphorylation of DARPP-32 at threonine-34 is required for cocaine action. Neuropsychopharmacology 31, 555562.
  • 35
    Marais R, Wynne J & Treisman R (1993) The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 73, 381393.
  • 36
    Xing J, Ginty DD & Greenberg ME (1996) Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273, 959963.
  • 37
    Gerfen CR, Miyachi S, Paletzki R & Brown P (2002) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22, 50425054.
  • 38
    Kim DS, Palmiter RD, Cummins A & Gerfen CR (2006) Reversal of supersensitive striatal dopamine D1 receptor signaling and extracellular signal-regulated kinase activity in dopamine-deficient mice. Neuroscience 137, 13811388.
  • 39
    Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, Corvol JC, Stipanovich A, Caboche J, Lombroso PJ, Nairn AC et al. (2005) Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci USA 102, 491496.
  • 40
    Carlezon WA Jr, Duman RS & Nestler EJ (2005) The many faces of CREB. Trends Neurosci 28, 436445.
  • 41
    Cole DG, Kobierski LA, Konradi C & Hyman SE (1994) 6-Hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons. Proc Natl Acad Sci USA 91, 96319635.
  • 42
    Andersson M, Hilbertson A & Cenci MA (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson’s disease. Neurobiol Dis 6, 461474.
  • 43
    Carta AR, Tronci E, Pinna A & Morelli M (2005) Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment. Eur J Neurosci 21, 11961204.
  • 44
    Sgambato-Faure V, Buggia V, Gilbert F, Levesque D, Benabid AL & Berger F (2005) Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol 64, 936947.
  • 45
    St-Hilaire M, Landry E, Levesque D & Rouillard C (2003) Denervation and repeated L-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats. Neurobiol Dis 14, 98109.
  • 46
    St-Hilaire M, Bourhis E, Levesque D & Rouillard C (2006) Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice. Eur J Neurosci 24, 795805.
  • 47
    Samadi P, Bedard PJ & Rouillard C (2006) Opioids and motor complications in Parkinson’s disease. Trends Pharmacol Sci 27, 512517.
  • 48
    Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P & Schwartz JC (1997) Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94, 33633367.
  • 49
    Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C & Sokoloff P (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9, 762767.
  • 50
    Bordet R, Ridray S, Schwartz JC & Sokoloff P (2000) Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12, 21172123.
  • 51
    Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC & Sokoloff P (2001) BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411, 8689.